Literature DB >> 18660827

A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice.

L F S Bastos1, A Angusti, M C Vilaça, L A Merlo, E B Nascimento, L T S Rocha, A M Godin, A G R Solano, S Jarussophon, E A Nunan, Y Konishi, M M Coelho.   

Abstract

BACKGROUND AND
PURPOSE: Many in vitro and fewer in vivo studies have shown that tetracyclines present anti-inflammatory activity. We investigated if a novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline, 12S-hydroxy-1,12-pyrazolinominocycline (PMIN), also induced antinociceptive and anti-inflammatory effects. EXPERIMENTAL APPROACH: Antibacterial effects against a minocycline-sensitive Staphylococcus aureus strain were evaluated by applying a cylinder-plate agar diffusion technique. Antibacterial effects of diluted serum from mice pre-treated with minocycline or PMIN were also evaluated. Ca2+ binding activity was assessed by spectrophotometry. Formalin-induced nociceptive responses and carrageenan-induced paw oedema were evaluated in mice. The rota-rod apparatus was used to evaluate motor coordination. KEY
RESULTS: Minocycline, but not PMIN, inhibited bacterial growth. Serum from mice treated with minocycline, but not with PMIN, also induced such an effect. The UV absorption spectrum of solutions of minocycline, but not those of PMIN, was markedly changed in the presence of Ca2+. Minocycline or PMIN inhibited both phases of formalin-induced nociception and carrageenan-induced paw oedema. It is unlikely that antinociception resulted from lack of motor coordination, as tetracycline did not impair the performance of mice on the rotating rod. CONCLUSIONS AND IMPLICATIONS: These results indicate that inhibition of nociception and oedema by tetracyclines is neither necessarily linked to antibacterial nor to Ca2+ chelating activities. This study supports the evaluation of the potential usefulness of PMIN in the treatment of painful and inflammatory diseases, as its lack of antibacterial and Ca2+ chelating activities might confer greater safety over conventional tetracyclines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18660827      PMCID: PMC2584916          DOI: 10.1038/bjp.2008.303

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

1.  Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines.

Authors:  M Tolomeo; S Grimaudo; S Milano; M La Rosa; V Ferlazzo; G Di Bella; C Barbera; D Simoni; P D'Agostino; E Cillari
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  Glia: a novel drug discovery target for clinical pain.

Authors:  Linda R Watkins; Steven F Maier
Journal:  Nat Rev Drug Discov       Date:  2003-12       Impact factor: 84.694

Review 3.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Authors:  Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

4.  Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line.

Authors:  P D'Agostino; V Ferlazzo; S Milano; M La Rosa; G Di Bella; R Caruso; C Barbera; S Grimaudo; M Tolomeo; S Feo; E Cillari
Journal:  Int Immunopharmacol       Date:  2001-09       Impact factor: 4.932

5.  Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy.

Authors:  Vasudeva Raghavendra; Flobert Tanga; Joyce A DeLeo
Journal:  J Pharmacol Exp Ther       Date:  2003-05-06       Impact factor: 4.030

Review 6.  Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature.

Authors:  A K Chow; J Cena; R Schulz
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

7.  Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.

Authors:  Maria Nikodemova; Jyoti J Watters; Samuel J Jackson; Shaun K Yang; Ian D Duncan
Journal:  J Biol Chem       Date:  2007-03-29       Impact factor: 5.157

8.  Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection.

Authors:  Susan C Fagan; David J Edwards; Cesar V Borlongan; Lin Xu; Ankur Arora; Giora Feuerstein; David C Hess
Journal:  Exp Neurol       Date:  2004-04       Impact factor: 5.330

9.  Efficient use of the iron ortho-nitrophenylporphyrin chloride to mimic biological oxidations of dimethylaminoantipyrine.

Authors:  Marc J Bazin; Helen Shi; Jeannine Delaney; Billie Kline; Zhendong Zhu; Cyrille Kuhn; Francoise Berlioz; Kathleen A Farley; Gwen Fate; Wing Lam; Gregory S Walker; Linning Yu; Michael P Pollastri
Journal:  Chem Biol Drug Des       Date:  2007-10       Impact factor: 2.817

10.  Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity.

Authors:  Millicent Stone; Paul R Fortin; Cesar Pacheco-Tena; Robert D Inman
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666

View more
  7 in total

1.  Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-α and CXCL-1 production and activating opioidergic mechanisms.

Authors:  Felipe F Rodrigues; Marcela I Morais; Ivo S F Melo; Paulo S A Augusto; Marcela M G B Dutra; Sarah O A M Costa; Fábio C Costa; Franciele A Goulart; Alysson V Braga; Márcio M Coelho; Renes R Machado
Journal:  Inflammopharmacology       Date:  2019-11-25       Impact factor: 4.473

Review 2.  Tetracyclines and pain.

Authors:  Leandro F S Bastos; Antônio C P de Oliveira; Linda R Watkins; Márcio F D Moraes; Márcio M Coelho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-27       Impact factor: 3.000

Review 3.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

4.  A minocycline derivative reduces nerve injury-induced allodynia, LPS-induced prostaglandin E2 microglial production and signaling via toll-like receptors 2 and 4.

Authors:  Leandro F S Bastos; Adriana M Godin; Yingning Zhang; Suwatchai Jarussophon; Bruno C S Ferreira; Renes R Machado; Steven F Maier; Yasuo Konishi; Rossimiriam P de Freitas; Bernd L Fiebich; Linda R Watkins; Márcio M Coelho; Márcio F D Moraes
Journal:  Neurosci Lett       Date:  2013-03-21       Impact factor: 3.046

5.  Diacylglycerol kinase α deficiency alters inflammation markers in adipose tissue in response to a high-fat diet.

Authors:  Emmani B M Nascimento; Louise Mannerås-Holm; Alexander V Chibalin; Marie Björnholm; Juleen R Zierath
Journal:  J Lipid Res       Date:  2017-12-12       Impact factor: 5.922

6.  Comparative Efficacy of Different Oral Doses of Clindamycin in Preventing Post-Operative Sequelae of Lower Third Molar Surgery-A Randomized, Triple-Blind Study.

Authors:  Anna Janas-Naze; Gaja Torbicka; Damian Chybicki; Małgorzata Lipczyńska-Lewandowska; Wei Zhang
Journal:  Medicina (Kaunas)       Date:  2022-05-17       Impact factor: 2.948

7.  Tetracycline-induced mitohormesis mediates disease tolerance against influenza.

Authors:  Adrienne Mottis; Terytty Y Li; Gaby El Alam; Alexis Rapin; Elena Katsyuba; David Liaskos; Davide D'Amico; Nicola L Harris; Mark C Grier; Laurent Mouchiroud; Mark L Nelson; Johan Auwerx
Journal:  J Clin Invest       Date:  2022-09-01       Impact factor: 19.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.